ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

trifluridine tipiracil drug combination

Also written as “TAS-102”, “Trifluridine/Tipiracil” and “Trifluridine and Tipiracil Tablets”.

Its studies are mostly in Colorectal Neoplasms · Breast Neoplasms · Kidney Diseases · Small Cell Lung Carcinoma · Stomach Neoplasms, led by 11 companies.

Furthest: phase 3, since May 24, 201225 company-led studies, 7 open or runningNext primary completion: Aug 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsuka130 open or runningphase 3since May 24, 2012May 24, 2012none ahead
Sino Biopharmaceuticalits history only32 open or runningphase 3since Mar 6, 2026May 31, 2019Aug 2027phase 3 · NCT07483684
AbbVieits history only11 open or runningphase 3since Apr 7, 2026Apr 7, 2026May 2029phase 3 · NCT07525206
Criteriumits history only11 open or runningphase 2since Apr 30, 2025Apr 30, 2025Dec 31, 2027phase 2 · NCT06992258
Elevar Therapeuticsits history only10 open or runningphase 1since Aug 26, 2019Aug 26, 2019none ahead
GamaMabs Pharmaits history only10 open or runningphase 2since Jan 8, 2019Jan 8, 2019none ahead
Gilead Sciencesits history only11 open or runningphase 2since Apr 7, 2026Apr 7, 2026Dec 2028phase 2 · NCT07527858
Jiangsu HengRui Medicineits history only11 open or runningphase 3since Dec 26, 2023Dec 26, 2023none ahead
Lunan Pharmaceutical Groupits history only10 open or runningno phasesince Mar 19, 2026Mar 19, 2026none ahead
STCubeits history only11 open or runningphase 1since May 27, 2026May 27, 2026Jul 31, 2028phase 1 · NCT07656038

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Otsuka only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 24, 2012First study: phase 3 study in Colorectal NeoplasmsFirst studyNCT01607957 · 800 enrolled · United States, Australia, Austria and more
  2. May 24, 20132 phase 1 studiesNCT01867879, NCT01867866
  3. Jun 4, 2013Phase 1 study in Advanced Solid Tumors (Excluding Breast Cancer)NCT01874522 · 46 enrolled · United States
  4. Jul 12, 2013Phase 2 study in Small Cell Lung CarcinomaNCT01904253 · 18 enrolled · Germany, Italy, Japan
  5. Jul 19, 2013Phase 1 study in Advanced Gastrointestinal TumorsNCT01916447 · 65 enrolled · United States
  6. Sep 19, 2013Phase 3 study in Colorectal NeoplasmsNCT01955837 · 406 enrolled · China, Korea, Republic of, Thailand
  7. Dec 18, 2013Phase 1 study in Advanced Solid TumorsNCT02031055 · 8 enrolled · United States
  8. Sep 30, 2014Phase 1 study in Advanced or Metastatic Solid TumorsNCT02261532 · 15 enrolled · China
  9. Nov 13, 20142 phase 1 studiesNCT02301117, NCT02301104
  10. Jul 13, 2015Phase 3 study in Stomach NeoplasmsNCT02500043 · 507 enrolled · United States, Belarus, Belgium and more
  11. Jul 13, 2016Phase 2 study in Colorectal NeoplasmsNCT02860546 · 18 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 13 Otsuka leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02860546Colorectal Neoplasms · United States2CompletedAug 201718
NCT02500043Stomach Neoplasms · United States, Belarus, Belgium and more3CompletedApr 30, 2018507
NCT02301117Kidney Diseases · United States, Czechia, Serbia1CompletedJun 19, 201943
NCT02301104Liver Neoplasms · United States1CompletedJun 201624
NCT02261532Advanced or Metastatic Solid Tumors · China1CompletedOct 201515
NCT02031055Advanced Solid Tumors · United States1CompletedNov 20148
NCT01955837Colorectal Neoplasms · China, Korea, Republic of, Thailand3CompletedFeb 16, 2016406
NCT01916447Advanced Gastrointestinal Tumors · United States1CompletedSep 201765
NCT01904253Small Cell Lung Carcinoma · Germany, Italy, Japan2TerminatedJun 201418
NCT01874522Advanced Solid Tumors (Excluding Breast Cancer) · United States1CompletedAug 201546
NCT01867879Advanced Solid Tumors (Excluding Breast Cancer) · United States1CompletedAug 201444
NCT01867866Advanced Solid Tumors · United States1CompletedOct 201344
NCT01607957Colorectal Neoplasms · United States, Australia, Austria and more3CompletedJan 31, 2014800

How it is read

Names in the registry

  • “TAS-102”, 11 entries
  • “Trifluridine/Tipiracil”, 3 entries
  • “Trifluridine and Tipiracil Tablets”, 2 entries
  • “Trifluridine-Tipiracil”, 1 entry
  • “Fruquintinib+ Lonsurf (trifluridine and tipiracil)”, 1 entry

Codes read as this program: TAS102.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.